a clear trendgold
In addition to the tumor shrinkage achieved by NDAT–paclitaxel ( Figure 3A ), a clear trend in the reduction in tumor cell viability measured with IVIS reveals a trend in advantage of NDAT–paclitaxel over other drug formulations despite the small tumor size ( Figure 4 ).